arrow
返回

Schizophrenia

delete2009-08-01
delete2.2K
PRE
AI
J
Jim van Os *
S
Shitij Kapur
DOI:10.1016/S0140-6736(09)60995-8delete
delete原文链接
delete原文求助
delete分享
delete收藏
摘要

摘要

En 中文
Schizophrenia is still one of the most mysterious and costliest mental disorders in terms of human suffering and societal expenditure. Here, we focus on the key developments in biology, epidemiology, and pharmacology of schizophrenia and provide a syndromal framework in which these aspects can be understood together. Symptoms typically emerge in adolescence and early adulthood. The incidence of the disorder varies greatly across places and migrant groups, as do symptoms, course, and treatment response across individuals. Genetic vulnerability is shared in part with bipolar disorder and recent molecular genetic findings also indicate an overlap with developmental disorders such as autism. The diagnosis of schizophrenia is associated with demonstrable alterations in brain structure and changes in dopamine neurotransmission, the latter being directly related to hallucinations and delusions. Pharmacological treatments, which block the dopamine system, are effective for delusions and hallucinations but less so for disabling cognitive and motivational impairments. Specific vocational and psychological interventions, in combination with antipsychotic medication in a context of community-case management, can improve functional outcome but are not widely available. 100 years after being so named, research is beginning to understand the biological mechanisms underlying the symptoms of schizophrenia and the psychosocial factors that moderate their expression. Although current treatments provide control rather than cure, long-term hospitalisation is not required and prognosis is better than traditionally assumed.
Keyword:
GENE-ENVIRONMENT INTERACTIONS
RANDOMIZED CONTROLLED-TRIAL
CANNABIS-INDUCED PSYCHOSIS
SEVERE MENTAL-ILLNESS
FOLLOW-UP
1ST-EPISODE SCHIZOPHRENIA
BIPOLAR DISORDER
LONG-TERM
SCHIZOAFFECTIVE DISORDER
NONAFFECTIVE PSYCHOSES
AI总结

AI总结

对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。

期刊

The Lancet 封面图
The Lancet
IF:
88.5
论文数:
5.4W
被引数:
34.8W

机构

M
Maastricht University
学者数:
3.1W
论文数: 2.8W
被引数: 277
U
university of london
学者数:
21.5W
论文数: 19.7W
被引数: 305
引用论文

引用论文

The effectiveness of supported employment for people with severe mental illness:: a randomised controlled trial
errLANCET
IF88.5
err2007-09-01
err442
errOAAI
errBurns, Tom; Catty, Jocelyn; Becker, Thomas; Drake, Robert E.; Fioritti, Angelo; Knapp, Martin; Lauber, Christoph; Rossler, Wulf; Tomov, Toma; van Busschbach, Jooske; White, Sarah; Wiersma, Durk
err分享
err收藏
Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey
errLANCET
IF88.5
err2009-01-01
err884
PREAI
errThornicroft, Graham; Brohan, Etaine; Rose, Diana; Sartorius, Norman; Leese, Morven
err分享
err收藏
Incidence of schizophrenia in ethnic minorities in London: ecological study into interactions with environment
err2001-12-08
err314
errOAAI
errBoydell, J; van Os, J; McKenzie, K; Allardyce, J; Goel, R; McCreadie, RG; Murray, RM
err分享
err收藏
Meta-Analysis of Gray Matter Anomalies in Schizophrenia: Application of Anatomic Likelihood Estimation and Network Analysis精神分裂症灰质异常的Meta分析: 解剖学似然估计和网络分析的应用
err2008-11-01
err556
errOAAI
errGlahn, David C.; Laird, Angela R.; Ellison-Wright, Ian; Thelen, Sarah M.; Robinson, Jennifer L.; Lancaster, Jack L.; Bullmore, Edward T.; Fox, Peter T.
err分享
err收藏
The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards - a cluster randomized controlled trial
err2007-09-10
err51
errOAAI
errThompson, A.; Sullivan, S. A.; Barley, M.; Strange, S. A.; Moore, L.; Rogers, P.; Sipos, A.; Harrison, G.
err分享
err收藏
Early intervention for psychosis
err2006-10-18
err275
PREAI
errMarshall, M.; Rathbone, J.
err分享
err收藏
学者 查看更多内容